Holen Sie sich die Stockscreener-App
9.01
3.22%
-0.30
Schlusskurs vom Vortag:
$9.31
Offen:
$9.465
24-Stunden-Volumen:
1.17M
Relative Volume:
0.70
Marktkapitalisierung:
$799.86M
Einnahmen:
$71.64M
Nettoeinkommen (Verlust:
$-294.57M
KGV:
-2.6912
EPS:
-3.348
Netto-Cashflow:
$-84.46M
1W Leistung:
-13.28%
1M Leistung:
-17.87%
6M Leistung:
+10.96%
1J Leistung:
+48.93%
1-Tages-Spanne:
$8.87
$9.465
1-Wochen-Bereich:
$8.82
$10.77
52-Wochen-Spanne:
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.01 | 901.06M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Lake Street | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Neutral |
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
KURA Reiterates by Wedbush -- Price Target Maintained at $36 - GuruFocus
Kura Oncology Inc (KURA) Institutional Confidence - TradingKey
KURA|Kura Oncology Inc|Price:10.150|Chg%:-0.240 - TradingKey
Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinoma - Bitget
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Kura Oncology Reports 50% Response Rate in RCC Combination Study - Yahoo Finance
Kura Oncology Market Sentiment - Benzinga España
Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial - Bitget
KURA Shows Promising Results in Phase 1a Kidney Cancer Trial - GuruFocus
Kura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma - Quiver Quantitative
Kura's Drug Combo Shows 13-Month Median Without Progression - Stock Titan
Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kura Oncology Inc (KURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Why Did KURA Stock Jump 13% In Pre-Market Today? - Stocktwits
Kura Oncology Inc (KURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kura Oncology Inc (KURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
KURA|Kura Oncology Inc|Price:10.499|Chg%:+0.109 - TradingKey
Kura Oncology Inc (KURA) Cash Flow - TradingKey
KURA|Kura Oncology Inc|Price:10.690|Chg%:+0.300 - TradingKey
KURA|Kura Oncology Inc|Price:10.390|Chg%:-0.060 - TradingKey
Enterprise value to EBIT forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology, Inc. (KURA) Stock Analysis: Exploring a Promising 198% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Bank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA) - The Globe and Mail
Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
(KURA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Barclays Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Is Kura Oncology (KURA) Undervalued On New FIT 001 Trial Data? - Yahoo Finance
Is Kura Oncology (KURA) Turning Darlifarnib Into a Foundational Precision Combo Platform? - Sahm
Enterprise value to revenue forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology presents new data supporting darl... - Pluang
Kura Oncology to Present First Long-Term Follow-Up Data - GlobeNewswire
Long-term kidney cancer data from Kura's drug due July 24 - Stock Titan
Enterprise value to EBITDA forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Price to earnings forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Price to sales forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Price to book forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win (NASDAQ:KURA) - Seeking Alpha
Kura Oncology (KURA) Jefferies London Healthcare Conference 2025 Summary - Quartr
Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story? - Yahoo Finance
Kura Oncology outlines targeted cancer pipeline as investors watch clinical milestones - Ad-hoc-news.de
Kura Oncology (KURA) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary - Quartr
Kura Oncology (KURA) Gains Nearly 3% as Shares Test Key Resistance ZoneAnalyst Downgrade Signals - dars.gov.et
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Kura Oncology reports $5.8 million revenue in Q1 2026 - scanx.trade
Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2500 Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2000 Growth Benchmark - marketscreener.com
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):